Table 2.
Comparison of subjects with and without steatosis(n=69)
| Characteristic | No steatosis (n=46) | Steatosis (n=23) | P |
|---|---|---|---|
| Age, years | 15.9 ± 2.9 | 16.3 ± 3.0 | 0.55 |
| Female sex | 18 (39%) | 8 (35%) | 0.73 |
| Anthropometry | |||
| BMI (kg/m2) | 20.9 (18.5, 23.3) | 28.7 (25.4, 36.4) | <0.0001 |
| BMI percentile (among 63 subjects <20y) | 60.8 (20.9, 86.8) | 96.4 (84.4, 98.7) | <0.0001 |
| BMI z-score (among 63 subjects <20y) | 0.28 (−0.81, 1.12) | 1.79 (1.01, 2.22) | <0.0001 |
| Liver disease diagnosis | <0.0001 | ||
| Autoimmune hepatitis (includes drug-induced + PSC overlap) | 18 (39) | 0 (0) | |
| NAFLD (n=10 NASH) | 0 (0) | 14 (61) | |
| Viral hepatitis | 9 (20) | 4 (17) | |
| Wilson’s disease/Alpha 1 antitrypsin deficiency | 2 (4) | 1 (4) | |
| Cellular rejection | 1 (2) | 0 (0) | |
| Cholestasis (includes PFIC) | 0 (0) | 1 (4) | |
| Other1 | 16 (35) | 3 (13) | |
| Blood tests nearest to time of CAP | |||
| ALT, U/L (n=62) | 63 (41, 151) | 129 (86, 262) | 0.07 |
| AST, U/L (n=56) | 41 (33, 80) | 66 (43, 129) | 0.13 |
| GGTP, U/L (n=49) | 84 (27, 161) | 83 (56, 118) | 0.57 |
1
7 with PSC, 5 with chronic hepatitis of unknown etiology, 2 with lysosomalacid lipase deficiency, 1 routine liver biopsy at the time of bariatric surgery, 1 with diabetes associated glycogenic hepatopathy, 1 with veno-occlusive disease, 1 with nodular regenerative hyperplasia, and 1 with severe combined immunodeficiency s/p stem cell transplant